MX2021002422A - Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide. - Google Patents

Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.

Info

Publication number
MX2021002422A
MX2021002422A MX2021002422A MX2021002422A MX2021002422A MX 2021002422 A MX2021002422 A MX 2021002422A MX 2021002422 A MX2021002422 A MX 2021002422A MX 2021002422 A MX2021002422 A MX 2021002422A MX 2021002422 A MX2021002422 A MX 2021002422A
Authority
MX
Mexico
Prior art keywords
methods
rheumatoid arthritis
compositions
treating subjects
subjects
Prior art date
Application number
MX2021002422A
Other languages
English (en)
Spanish (es)
Inventor
Neil Graham
Anita Boyapati
Toshio Kimura
Jérôme Msihid
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021002422A publication Critical patent/MX2021002422A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
MX2021002422A 2018-08-29 2019-08-28 Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide. MX2021002422A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862724212P 2018-08-29 2018-08-29
US201862747301P 2018-10-18 2018-10-18
US201962798697P 2019-01-30 2019-01-30
US201962824399P 2019-03-27 2019-03-27
US201962856431P 2019-06-03 2019-06-03
US201962858443P 2019-06-07 2019-06-07
EP19192387 2019-08-19
PCT/US2019/048460 WO2020047029A1 (en) 2018-08-29 2019-08-28 Methods and compositions for treating subjects having rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX2021002422A true MX2021002422A (es) 2021-07-15

Family

ID=67851236

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021002422A MX2021002422A (es) 2018-08-29 2019-08-28 Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
MX2025010592A MX2025010592A (es) 2018-08-29 2021-02-26 Metodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025010592A MX2025010592A (es) 2018-08-29 2021-02-26 Metodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide

Country Status (16)

Country Link
US (2) US11319375B2 (cg-RX-API-DMAC7.html)
EP (1) EP3843852A1 (cg-RX-API-DMAC7.html)
JP (1) JP7504871B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260109977A (cg-RX-API-DMAC7.html)
CN (1) CN112955222A (cg-RX-API-DMAC7.html)
AU (2) AU2019329958B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003206A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110891A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000483A1 (cg-RX-API-DMAC7.html)
IL (1) IL280824A (cg-RX-API-DMAC7.html)
MA (1) MA53481A (cg-RX-API-DMAC7.html)
MX (2) MX2021002422A (cg-RX-API-DMAC7.html)
PH (1) PH12021550416A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101674QA (cg-RX-API-DMAC7.html)
TW (2) TW202532441A (cg-RX-API-DMAC7.html)
WO (1) WO2020047029A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
FR3095698B1 (fr) * 2019-05-03 2021-05-07 Sinnovial Procédé d’estimation de l’efficacité de traitement par un agent anti-CD20 chez un patient atteint de polyarthrite rhumatoïde et en réponse inadéquate a au moins une biothérapie
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
CA3180369A1 (en) * 2020-05-26 2021-12-02 Inka Albrecht Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
KR20230031015A (ko) * 2021-08-26 2023-03-07 주식회사 이뮨메드 자가면역질환의 예방 또는 치료를 위한 항체의약품
CN117138126B (zh) * 2023-08-30 2024-04-09 江苏恰瑞生物科技有限公司 定向清除炎症因子il-6的过滤材料及过滤柱

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE07012626T1 (de) 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
EP1224189B1 (en) 1999-10-07 2006-01-25 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
AU2005247341B2 (en) 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
FR2920033B1 (fr) 2007-08-13 2014-08-22 Snecma Turbomachine avec diffuseur
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
RU2565809C2 (ru) 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2011006273A1 (en) * 2009-07-15 2011-01-20 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112012028557A2 (pt) 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
CA2824089A1 (en) * 2011-02-03 2012-08-09 Santarus, Inc. Selection and treatment of subjects
TWI568888B (zh) 2011-09-15 2017-02-01 第諾拉工業公司 氣體擴散電極及其製法和電化電解池
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US9387246B2 (en) * 2013-09-03 2016-07-12 L. Douglas Graham Treatment methods for rheumatoid arthritis
KR20230155586A (ko) 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
WO2015116852A1 (en) * 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
JP7101479B2 (ja) 2014-09-16 2022-07-15 サノフィ・バイオテクノロジー 関節リウマチ患者の健康に関連した生活の質を改善するための組成物
BR112018008900A8 (pt) 2015-11-03 2019-02-26 Regeneron Pharma composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
KR20230093522A (ko) * 2016-03-07 2023-06-27 사노피 바이오테크놀로지 류마티스 관절염의 치료를 위한 조성물 및 방법
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis

Also Published As

Publication number Publication date
CA3110891A1 (en) 2020-03-05
US20200102395A1 (en) 2020-04-02
AU2019329958A1 (en) 2021-03-18
JP7504871B2 (ja) 2024-06-24
IL280824A (en) 2021-04-29
SG11202101674QA (en) 2021-03-30
EP3843852A1 (en) 2021-07-07
WO2020047029A1 (en) 2020-03-05
TW202026035A (zh) 2020-07-16
TWI868074B (zh) 2025-01-01
US20230059376A1 (en) 2023-02-23
AU2019329958B2 (en) 2025-05-29
KR20260109977A (ko) 2026-07-13
MA53481A (fr) 2021-07-07
BR112021003206A2 (pt) 2021-05-25
KR20210049871A (ko) 2021-05-06
CN112955222A (zh) 2021-06-11
PH12021550416A1 (en) 2021-09-27
AU2025203365A1 (en) 2025-05-29
TW202532441A (zh) 2025-08-16
US11319375B2 (en) 2022-05-03
CL2021000483A1 (es) 2021-07-19
JP2022502350A (ja) 2022-01-11
MX2025010592A (es) 2025-10-01

Similar Documents

Publication Publication Date Title
PH12021550416A1 (en) Methods and compositions for treating subjects having rheumatoid arthritis
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
PH12021550020A1 (en) High-affinity, isoform-selective tgf#1 inhibitors and use thereof
MY209489A (en) Antibody against human il-4ra and use thereof
EP3882268A4 (en) ANTI-CD73 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF
PH12020552229A1 (en) Il-11ra antibodies
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
ZA202205817B (en) Antibodies recognizing tau
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12021551048A1 (en) Antibodies recognizing tau
ZA201905866B (en) Anti-c5 antibodies and uses thereof
MX2020005433A (es) Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina.
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
MX2020008122A (es) Anticuerpos anti-pd-1.
NZ763061A (en) Anti-ox40 antibodies and uses thereof
PH12022552725A1 (en) Anti-ox40 antibody and uses thereof
MY194084A (en) Interferon beta antibodies and uses thereof
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
AU2018448903A8 (en) Antibodies recognizing tau
EP4006055A4 (en) ANTI-BCMA ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
MX2025000992A (es) Anticuerpos anti-cd40 y usos de los mismos